MK-4334
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $23,084 | 2 | 0 |
| 2019 | $6,908 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $29,992 | 5 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Two-Part Investigation of the Changes in Glutamate,Glutamine Metabolism Induced by Ketamine and MK-4334 in the Prefrontal Cortex of Healthy Adult Males Measured Using Selective Proton-Observed, Carbon-Edited Magnetic Resonance Spectroscopy | Merck Sharp & Dohme Corporation | $23,084 | 0 |
| A Randomized, Double-Blinded Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MK-4334 in Participants With Alzheimer s Clinical Syndrome on a Stable Dose of Donepezil | Merck Sharp & Dohme Corporation | $6,908 | 0 |
Top Doctors Receiving Payments for MK-4334
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Salt Lake City, UT | $29,992 | 5 |
Manufacturing Companies
- Merck Sharp & Dohme Corporation $29,992
Product Information
- Type Drug
- Total Payments $29,992
- Total Doctors 0
- Transactions 5
About MK-4334
MK-4334 is a drug associated with $29,992 in payments to 0 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2019 to 2020. In 2020, $23,084 was paid across 2 transactions to 0 doctors.
The most common payment nature for MK-4334 is "Unspecified" ($29,992, 100.0% of total).
MK-4334 is associated with 2 research studies, including "A Two-Part Investigation of the Changes in Glutamate,Glutamine Metabolism Induced by Ketamine and MK-4334 in the Prefrontal Cortex of Healthy Adult Males Measured Using Selective Proton-Observed, Carbon-Edited Magnetic Resonance Spectroscopy" ($23,084).